%0 Journal Article
%A Zabana, Yamile
%A Marin-Jimenez, Ignacio
%A Rodriguez-Lago, Iago
%A Vera, Isabel
%A Martin-Arranz, Maria Dolores
%A Guerra, Ivan
%A Gisbert, Javier P
%A Mesonero, Francisco
%A Benitez, Olga
%A Taxonera, Carlos
%A Ponferrada-Diaz, Angel
%A Piqueras, Marta
%A Lucendo, Alfredo J
%A Caballol, Berta
%A Mañosa, Miriam
%A Martinez-Montiel, Pilar
%A Bosca-Watts, Maia
%A Gordillo, Jordi
%A Bujanda, Luis
%A Manceñido, Noemi
%A Martinez-Perez, Teresa
%A Lopez, Alicia
%A Rodriguez-Gutierrez, Cristina
%A Garcia-Lopez, Santiago
%A Vega, Pablo
%A Rivero, Montserrat
%A Melcarne, Luigi
%A Calvo, Maria
%A Iborra, Marisa
%A Barreiro de-Acosta, Manuel
%A Sicilia, Beatriz
%A Barrio, Jesus
%A Perez, Jose Lazaro
%A Busquets, David
%A Perez-Martinez, Isabel
%A Navarro-Llavat, Merce
%A Hernandez, Vicent
%A Arguelles-Arias, Federico
%A Ramirez Esteso, Fernando
%A Meijide, Susana
%A Ramos, Laura
%A Gomollon, Fernando
%A Muñoz, Fernando
%A Suris, Gerard
%A de Zarate, Jone Ortiz
%A Huguet, Jose Maria
%A Llao, Jordina
%A Garcia-Sepulcre, Mariana Fe
%A Sierra, Monica
%A Dura, Miguel
%A Estrecha, Sandra
%A Fuentes Coronel, Ana
%A Hinojosa, Esther
%A Olivan, Lorenzo
%A Iglesias, Eva
%A Gutierrez, Ana
%A Varela, Pilar
%A Rull, Nuria
%A Gilabert, Pau
%A Hernandez-Camba, Alejandro
%A Brotons, Alicia
%A Ginard, Daniel
%A Sese, Eva
%A Carpio, Daniel
%A Aceituno, Montserrat
%A Cabriada, Jose Luis
%A Gonzalez-Lama, Yago
%A Jimenez, Laura
%A Chaparro, Maria
%A Lopez-San Roman, Antonio
%A Alba, Cristina
%A Plaza-Santos, Rocio
%A Mena, Raquel
%A Tamarit-Sebastian, Sonsoles
%A Ricart, Elena
%A Calafat, Margalida
%A Olivares, Sonsoles
%A Navarro, Pablo
%A Bertoletti, Federico
%A Alonso-Galan, Horacio
%A Pajares, Ramon
%A Olcina, Pablo
%A Manzano, Pamela
%A Domenech, Eugeni
%A Esteve, Maria
%T Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry.
%D 2022
%@ 2077-0383
%U http://hdl.handle.net/10668/21235
%X We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged ≥ 60 years (OR 7.1, 95% CI: 1.8-27 and 4.5, 95% CI: 1.3-15.9), while having ≥2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3-11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD.
%K COVID-19
%K SARS-CoV-2
%K Inflammatory bowel disease
%~